Scientists have developed a computer-based model that may explain how nerve cells become damaged in ALS, and how best to time ...

A new survey suggests many people with ALS would value even modest slowing of ALS progression as a treatment goal.

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein can prevent neuron death caused by DNA damage and p53 activation in ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) ...

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with no cure and limited treatment options.

The MarketWatch News Department was not involved in the creation of this content. The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients LOS ANGELES, Nov. 4, ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

Achieving 100 enrolled patients in the NIH‑funded SEANOBI Expanded‑Access Program marks substantial progress in the clinical development of MN‑166. We are deeply grateful to the patients and families ...